16 completed. 16 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 16 | Completed 16 |
| Phase 2 | 2 | Completed 2 |
Follow Osteopenia: new trials by email Literature Review of Osteopenia trials Research Report on Osteopenia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of a Ghrelin Receptor Agonist on Muscle and Bone Anamorelin Hydrochloride, Placebo - Sarcopenia, Osteopenia | Phase 1 | Completed | Tufts University | 32 | 2019-12-05 | 2024-03-27 |
| Safety and Tolerability of Intravenous LLP2A-Alendronate for Osteopenia Secondary to Glucocorticoids LLP2A-ALENDRONATE, Placebo - Osteopenia, Osteoporosis | Phase 1 | Completed | Nancy E. Lane, MD | 58 | 2016-10-14 | 2021-08-06 |
| Melatonin-Micronutrients for Osteopenia Treatment Study Fiber Pill, Melatonin, Strontium citrate, Vitamins D3 and K2 - Osteoporosis, Osteopenia | Phase 1 | Completed | Duquesne University | 23 | 2013-08-01 | 2018-06-14 |
| The Effect of Chymosin on the Intestinal Absorption of Calcium Drug A Chymosin, Drug B: Placebo - Osteoporosis, Osteopenia | Phase 1 | Completed | University of Aarhus | 125 | 2011-04-01 | 2012-03-21 |
| Safety And Tolerability Study Of RN564 In Women With Osteopenia And Healthy Men. RN564 - Osteopenia, Osteoporosis | Phase 1 | Completed | Pfizer | 68 | 2011-04-01 | 2024-09-24 |
| An Ascending Multiple Dose Study Evaluating AMG 167 in Healthy Men and Postmenopausal Women With Low Bone Mineral Density Placebo, AMG 167 - Osteopenia | Phase 1 | Completed | Amgen | 74 | 2010-06-01 | 2018-09-06 |
| A Single-dose Study Evaluating Romosozumab (AMG 785) in Healthy Postmenopausal Japanese and Non-Japanese Women Romosozumab, Placebo - Osteopenia | Phase 1 | Completed | Amgen | 31 | 2010-05-03 | 2019-07-31 |
| A Study to Evaluate the Effect of Romosozumab (AMG 785) on Bone Quality of the Forearm in Postmenopausal Women With Low Bone Mass Romosozumab, Placebo - Osteopenia | Phase 1 | Completed | Amgen | 24 | 2009-08-18 | 2019-07-05 |
| A First-in-human Study Evaluating AMG 167 in Healthy Men and Postmenopausal Women AMG 167, Placebo - Osteopenia | Phase 1 | Completed | Amgen | 69 | 2009-05-01 | 2010-04-02 |
| Melatonin Osteoporosis Prevention Study melatonin, sugar pill - Osteoporosis, Osteopenia | Phase 1 | Completed | Duquesne University | 19 | 2008-09-01 | 2012-03-13 |
| A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Romosozumab (AMG 785) Romosozumab, Placebo - Postmenopausal, Osteopenia | Phase 1 | Completed | Amgen | 48 | 2007-11-14 | 2023-08-30 |
| A First-in-human Study Evaluating Romosozumab (AMG 785) in Healthy Men and Postmenopausal Women Romosozumab, Placebo - Osteopenia | Phase 1 | Completed | Amgen | 74 | 2006-12-13 | 2019-07-05 |
| Isoflavones for Promoting Calcium Absorption and Preventing Bone Loss in Post Menopausal Women Genistein vs Risedronate - Osteoporosis, Osteopenia | Phase 1 | Completed | Purdue University | 23 | 2006-01-01 | 2018-05-04 |
| Electromagnetic Treatment For Bone Loss After Forearm Fracture Pulsing electromagnetic field (PEMF) - Bone Disease, Metabolic, Osteopenia | Phase 1 / Phase 2 | Completed | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 80 | 2003-11-01 | 2015-12-23 |
| Pharmacokinetics of a Single 14C-labeled Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose risedronate, alendronate - Osteopenia, Osteoporosis | Phase 1 | Completed | Warner Chilcott | 32 | 2002-11-01 | 2013-04-17 |
| Encouraging Calcium Absorption and Bone Formation During Early Puberty Nondigestible oligosaccharide (NDO) - Osteoporosis, Osteopenia | Phase 1 / Phase 2 | Completed | Baylor College of Medicine | 100 | 2001-05-01 | 2015-07-24 |
Bone Diseases, Metabolic (16) · Osteoporosis (9) · Anxiety Disorders (1) · Bone Diseases (1) · Bone Resorption (1) · Depression (1) · Hypertension (1) · Osteonecrosis (1) · Sarcopenia (1)
Metabolic Diseases (16) · Musculoskeletal Diseases (16) · Nutritional and Metabolic Diseases (16) · Bone Diseases (15) · Pathological Conditions, Signs and Symptoms (2) · Atrophy (1) · Behavior (1) · Behavioral Symptoms (1) · Cardiovascular Diseases (1) · Mental Disorders (1) · Muscular Atrophy (1) · Necrosis (1) · Nervous System Diseases (1) · Neurologic Manifestations (1) · Neuromuscular Manifestations (1)
romosozumab (4) · Melatonin (2) · Risedronic Acid (2) · Alendronate (1) · Dietary Fiber (1) · Lactose (1) · Sugars (1) · Water (1) · anamorelin (1) · microcrystalline cellulose (1)
Amgen (6) · Duquesne University (2) · Baylor College of Medicine (1) · Nancy E. Lane, MD (1) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (1) · Pfizer (1) · Purdue University (1) · Tufts University (1) · University of Aarhus (1) · Warner Chilcott (1)
United States (9) · Denmark (1)
Paula A Witt-Enderby, PhD (2) · Amy Sun, MD, PhD (1) · Bess Dawson-Hughes, MD (1) · Connie M. Weaver, PhD (1) · Joseph A. Spadaro, PhD (1) · Judith L Balk, MD (1) · Leif Mosekilde, Professor (1) · Mark Swanson, ND (1) · Nancy E Lane, MD (1) · Steven A. Abrams, MD (1)
PMID 15883634, PMID 16076940, PMID 16087995, PMID 22220591, PMID 25271941, PMID 25515208, PMID 26245807
P50AT000477 (1), R01AR043740 (1), R21AR074138 (1)